Deutsche Bank analyst George Hill lowered the firm’s price target on CVS Health to $77 from $81 and keeps a Hold rating on the shares ahead of the Q4 report on February 7. While CVS will outgrow all of its peers in 2024, the company has “clearly upset the market dynamic and competitive balance” in the Medicare Advantage market at a time when utilization trends are on the rise, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVS:
- LLY, ABT, CVS: Which Healthcare Stock Do Analysts Prefer?
- Convey Health appoints Dan Finke as CEO
- CVS Health adds two new renewable energy projects with Constellation
- Tyson (NYSE:TSN) Drops CVS as a Health Benefits Provider
- CVS Health replaced at Tyson Foods by new pharmacy benefit manager, CNBC says
